← Back to patent-cliff list
马来酸茚达特罗/格隆溴铵
Tier B — Position earlyIndacaterol Maleate/Glycopyrronium Bromide
诺华制药
Originator
2013
First approval
-
Expiry (public)
$1.2B ▲
Peak sales
化学药
Type
Targets：mAChRs、ADRB2
Brand：Utibron Neohaler、Ultibro Breezhaler、杰润
Indications (approved)：慢性阻塞性肺疾病
Regional status
US
撤市
EU
批准上市
2013-09-18
China
批准上市
2017-12-28
Japan
批准上市
2013-09-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Indacaterol Maleate/Glycopyrronium Bromide?
Approved indications include: 慢性阻塞性肺疾病.
When does the Indacaterol Maleate/Glycopyrronium Bromide patent expire?
No public expiry year is available for Indacaterol Maleate/Glycopyrronium Bromide yet; this page updates once verified.
How do I get a quote for Indacaterol Maleate/Glycopyrronium Bromide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24